MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务。

Enzalutamide

CAS No. : 915087-33-1

MCE 国际站：Enzalutamide

产品活性：Enzalutamide (MDV3100) 是一种雄激素受体 (androgen receptor (AR)) 拮抗剂，在 LNCaP 前列腺细胞中抑制 AR 的 IC₅₀ 值为 36 nM。Enzalutamide 是一种自噬 (autophagy) 激活剂。

研究领域：Vitamin D Related/Nuclear Receptor  |  Autophagy

作用靶点：Androgen Receptor  |  Autophagy

In Vitro: Enzalutamide (MDV3100) has greater affinity to AR than ICI 176334 does in a competition assay with 16β-[¹⁸F]fluoro-5α-DHT (18-FDHT) in castration-resistant LNCaP/AR cells (AR-overexpressing). While Enzalutamide shows no agonism in LNCaP/AR prostate cells. Enzalutamide antagonizes induction of prostate-specific antigen (PSA) and transmembrane serine protease 2 (TMPRSS2), combination with the synthetic androgen R1881 in parental LNCaP cells. Enzalutamide inhibits the transcriptional activity of a mutant AR protein (W741C, mutation of Trp741 to Cys).
Enzalutamide also prevents nuclear translocation and co-activator recruitment of the ligand-receptor complex.

In Vivo: Enzalutamide (MDV3100) induces great tumor regression in castrate male mice bearing LNCaP/AR xenografts at a dose of 10 mg/kg.
Enzalutamide shows dose-independent pharmacokinetics at intravenous and oral doses of 0.5-5 mg/kg.

相关产品：Drug Repurposing Compound Library Plus  |  FDA-Approved Drug Library Plus  |  FDA-Approved Drug Library Mini  |  Bioactive Compound Library Plus  |  FDA-Approved Drug Library  |  Anti-Cancer Compound Library  |  Antiviral Compound Library  |  Autophagy Compound Library  |  Drug Repurposing Compound Library  |  NMPA-Approved Drug Library  |  Orally Active Compound Library  |  FDA Approved & Pharmacopeial Drug Library  |  Drug-Induced Liver Injury (DILI) Compound Library  |  Anti-Pancreatic Cancer Compound Library  |  Targeted Therapy Drug Library   |  Transcription Factor-Targeted Library  |  FDA-Approved Anticancer Drug Library  |  Human Metabolite Library  |  Anti-Prostate Cancer Compound Library  |  Nuclear Receptor Compound Library  |  Heterocyclic Compound Library  |  Cell Death Library  |  Bioactive Compound Library Max  |  DHEA  |  Bavdegalutamide  |  Medroxyprogesterone acetate  |  Darolutamide  |  Apalutamide  |  Bicalutamide  |  Spironolactone  |  Flutamide  |  Danazol  |  Lupeol  |  11-Ketodihydrotestosterone  |  Luxdegalutamide  |  ARCC-4  |  N-desmethyl Enzalutamide  |  BMS-564929  |  Masofaniten  |  Ailanthone  |  3,3'-Diindolylmethane  |  PROTAC AR-V7 degrader-1  |  UT-34  |  Cyproterone acetate  |  Adrenocorticotropic hormone TFA  |  Ostarine  |  VPC-14449  |  EPI-001  |  Ralaniten  |  BMS-986365  |  Vosilasarm  |  Drospirenone  |  MTX-23

热门产品线：重组蛋白  |  药物筛选  |  天然产物  |  荧光染料  |  PROTAC  |  同位素标记物

Trending products：Recombinant Proteins  |  Bioactive Screening Libraries  |  Natural Products  |  Dye Reagents  |  PROTAC  |  Isotope-Labeled Compounds

品牌介绍:
•   MCE (MedChemExpress) 拥有200 多种全球独家化合物库，我们致力于为全球科研客户提供前沿最全的高品质小分子活性化合物；
•   50,000 多种高选择性抑制剂、激动剂涉及各热门信号通路及疾病领域；
•   产品种类涵盖各种重组蛋白，多肽，常用试剂盒 ，更有 PROTAC、ADC 等特色产品，广泛应用于新药研发、生命科学等科研项目；
•   提供虚拟筛选，离子通道筛选，代谢组学分析检测分析，药物筛选等专业技术服务；
•   设有专业的实验中心和严格的质控、验证体系；
•   提供 LC/MS、NMR、HPLC、手性分析、元素分析等各项质检报告，确保产品的高纯度、高品质；
•   产品的生物活性多经各国客户实验验证；
•   Nature, Cell, Science 等多种顶级期刊及制药专利收录了MCE客户的科研成果；
•   专业团队跟踪最新的制药及生命科学研究进展，为您提供全球最新的活性化合物；
•   与世界各大制药公司及知名科研机构建立了长期的合作。